Eric Siemers

TL;DR: The Leon Thal Symposium 2009 was convened to explore strategies to surmount the barriers in designing a multisite, comparative study to evaluate and validate various approaches for detecting and selecting asymptomatic people at risk for cognitive disorders/dementia.

TL;DR: Solanezumab is an anti‐amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease and its mechanism suggests the possibility of slowing the progression of AD.

TL;DR: The iADRS demonstrated acceptable psychometric properties and was effective in capturing disease progression from MCI through moderate AD and treatment effects across the early disease spectrum, suggesting it can be used in studies of mixed populations, ensuring sensitivity to treatment effects as subjects progress during studies of putative disease-modifying agents.

TL;DR: Overall, the combination of MRI, ApoE, and cognitive scores provided the best trade-off between cost and time compared with other biomarker combinations for patient recruitment in clinical trial.

TL;DR: A more integrated understanding of the complex pathophysiology and progression of AD is needed to identify the appropriate pathways and the disease stage to target and to enable definition and evaluation of the appropriate dose and dosing regimen and determination of efficacy.